Global diabetes rates have surged, particularly in low-resource areas, revealing critical gaps in treatment access and ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Thursday is World Diabetes Day. Diabetes affects 40 million Americans and for most, the best form of treatment includes ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

While aging is the reason for gray hair and genetics being the most influential in terms of the timing, Dr. Gohara says ...

The University of Pittsburgh is studying ways to improve the lives of Type 2 diabetics, or people who just want to control their sugar levels.